The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study
Abstract
The article presents the results of a randomized comparative study of Aripiprazole and Quetiapine in the treatment of patients with a dual diagnosis: schizophrenia and substance use disorders. During the study, 90 of the 266 male patients were screened. Among them, 54 individuals (60%) had a previously established diagnosis of mental disorder and 36 patients (40%) had no established psychiatric diagnosis. They were randomly randomized into three groups of 30 patients, each receiving an antipsychotic: Aripiprazole at a dose of up to 20 mg daily, Quetiapine at a dose of up to 600 mg daily, or Haloperidol at a dose of up to 30 mg daily. The efficacy of Aripiprazole and Quetiapine was evaluated using the following scales: PANSS, BPRS, VAS, and Substance Craving Scale (SCS). Drug safety was assessed by the development of adverse events, serious adverse events, or adverse reactions. Study results demonstrated the efficacy of atypical antipsychotics in the three groups. Analysis of independent variables showed significant differences between Aripiprazole and Haloperidol in PANSS and BPRS scores by Visit 4, in VAS scores by Visit 3, and in SCS scores by Visit 2. Intergroup analysis of independent variables showed significant differences between Quetiapine and Haloperidol in PANSS, VAS, and SCS scores by Visit 4. Intergroup analysis of independent variables showed significant differences between Aripiprazole and Quetiapine in the VAS and SCS scores. The correlation analysis allowed dr…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“however, the effectiveness of such treatments remains inconclusive due to limited sample sizes and insufficient reporting in randomized controlled trials”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [31]
In the citing paper
“Pharmacological interventions, including medications such as clozapine, have shown promise in treating individuals with comorbid SUDs and psychiatric conditions, with research suggesting higher odds of abstinence and reduced psychiatric hospitalization”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [31]
Citations
Cites
Huskisson, E. C. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90884-8 · Cited by 4,522
McLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Cannabis Abuse and the Course of Recent-Onset Schizophrenic Disorders
Linszen, D. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040017002 · Cited by 656
Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624
Swendsen, J., Conway, K. P., Degenhardt, L., Glantz, M., Jin, R., Merikangas, K. R., Sampson, N., & Kessler, R. C. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.02902.x · Cited by 597
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes
DIXON, L. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00161-3 · Cited by 472
Ghaemi, S. N., Ko, J. Y., & Goodwin, F. E. I. K. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700202 · Cited by 456
The link between schizophrenia and substance use disorder: A unifying hypothesis
Khokhar, J. Y., Dwiel, L. L., Henricks, A. M., Doucette, W. T., & Green, A. I. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.016 · Cited by 281
Bramness, J. G., Gundersen, Ø. H., Guterstam, J., Rognli, E. B., Konstenius, M., Løberg, E.-M., Medhus, S., Tanum, L., & Franck, J. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-221 · Cited by 243
Green, A. I., Tohen, M. F., Hamer, R. M., Strakowski, S. M., Lieberman, J. A., Glick, I., & Scott Clark, W. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.08.001 · Cited by 195
Research works printed but not linked: 11
- Janoutová J, 2016, Neuro Endocrinol Lett, 37, 1
- European Monitoring Centre for Drugs and Drug Addiction, 2019, European Drug Report
- Kirzhanova VV, 2017, The basic parameters of activity of narcological service in the Russian Federation in 2015-2016. A statistical compendium
- Ipser JC, 2015, Cochrane Database Syst Rev, 1, CD007505
- Unglaub W, 2003, Psychiatr Prax, 30, S121–4
- Brunetti M, 2012, Eur Rev Med Pharmacol Sci, 16, 1346
- Indave BI, 2016, Cochrane Database Syst Rev, 3, CD006306
- Maksimov VG., 2009, J Trudny`j Pacient, 9, 42
- Saffar SP, 2007, S D Med, 60, 439
- Overall E, 1988, Psychopharmacol Bull, 97
- Ivanets NN, 2001, Zhurnal Nevropatologii i Psixiatrii im. S.S.Korsakova, 8, 4
Cited by
Bahji, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040999 · Cited by 83
“…of such treatments remains inconclusive due to limited sample sizes and insufficient reporting in randomized controlled trials, emphasizing the importance of integrating medication into a comprehensive treatment approach that includes psychotherapeutic interventions and social support [29–31].”
Background
Metadata
- Authors
- Skryabin, V. Y., Vinnikova, M. A., Ezhkova, E. V., Titkov, M. S., & Bulatova, R. A.
- Affiliations
- Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia
- Psychiatry and Psychotherapy Division, European Medical Centre, Moscow, Russia
- ORCID
- Skryabin, V. Yu.
- Venue
- Journal of Addictive Diseases
- Publisher
- Informa UK Limited
- Published
- 2021-04-09
- Volume
- 39
- Issue
- 4
- Pages
- 513-525
- ISSN
- 1055-0887 (ISSN-L)
- 1545-0848
- OpenAlex
- W3142311157
- Cited by
- 17
- References
- 38
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 4
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Addictive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- atypical antipsychotics, dual diagnosis, schizophrenia spectrum disorders, substance use disorders, aripiprazole, quetiapine, haloperidol, drug craving, symptom severity, adverse drug reactions, PANSS, Brief Psychiatric Rating Scale
- MeSH terms
- Aripiprazole, Quetiapine Fumarate, Adult, Haloperidol, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Schizophrenia, Antipsychotic Agents, Treatment Outcome, Diagnosis, Dual (Psychiatry), Substance-Related Disorders, Young Adult, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study. https://app.cochat.ai/papers/10.1080/10550887.2021.1905589
- The paper
- Skryabin, V. Y., Vinnikova, M. A., Ezhkova, E. V., Titkov, M. S., & Bulatova, R. A. (2021). Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study. Journal of Addictive Diseases. https://doi.org/10.1080/10550887.2021.1905589
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.